Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at Piper Sandler

Key Points

• Piper Sandler raised its Teva price target from $44 to $56 and maintained an Overweight rating, implying about 29.7% upside from the previous close.
• Analyst sentiment is broadly positive: the consensus rating is Moderate Buy, with a $48.15 average price target; 13 analysts rate the stock Buy.
• Teva beat quarterly earnings and revenue estimates, reporting EPS of $0.86 versus $0.72 expected and revenue of $4.39 billion versus $4.23 billion, though revenue fell 1.9% year over year.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price objective raised by research analysts at Piper Sandler from $44.00 to $56.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's target price would indicate a potential upside of 29.72% from the company's previous close.

A number of other equities research analysts have also issued reports on the stock. Oppenheimer upped their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a report on Friday, October 9th. TD Cowen lifted their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, November 4th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Finally, Barclays raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an "overweight" rating in a report on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.15.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $43.17 on Thursday. Teva Pharmaceutical Industries has a 1 year low of $24.01 and a 1 year high of $43.34. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The firm has a market capitalization of $50.30 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 3.97 and a beta of 0.97. The business has a 50 day simple moving average of $39.88 and a 200-day simple moving average of $34.96.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period last year, the company earned $0.78 EPS. The company's revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 367,600 shares of the company's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Sabag sold 46,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares of the company's stock, valued at $3,386,266.80. This trade represents a 36.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 420,942 shares of company stock valued at $16,572,473 over the last quarter. 0.54% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the business. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $33,000. Cornerstone Planning Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after purchasing an additional 755 shares during the period. Western Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $43,000. Sunbelt Securities Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $45,000. Finally, CX Institutional acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries News Roundup

These are some of the TEVA news items that stood out recently:

• Positive Sentiment: R&D updates highlighted prospective first-in-class treatments for Tourette syndrome, celiac disease and scarring associated with inflammatory bowel disease. These programs could strengthen Teva’s future pipeline, although development and commercial outcomes remain uncertain. Teva pipeline report
• Neutral Sentiment: HC Wainwright maintained a Buy rating and $52 price target, raising its FY2027 EPS estimate to $3.07 from $3.03. However, it also cut some quarterly estimates, including Q4 2026 EPS to $0.64 from $0.75, making the revisions mixed overall. HC Wainwright estimates
• Negative Sentiment: Healthcare shares traded lower Wednesday afternoon, a sector-wide headwind that could weigh on TEVA independently of company-specific developments. Healthcare sector update

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.